Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Unicycive Therapeutics (UNCY – Research Report) and Nurix Therapeutics (NRIX – Research Report) with bullish sentiments.

Unicycive Therapeutics (UNCY)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Unicycive Therapeutics today and set a price target of $4.50. The company’s shares closed last Tuesday at $1.09.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.8% and a 38.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and Madrigal Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unicycive Therapeutics with a $5.88 average price target, a 406.9% upside from current levels. In a report released today, Noble Financial also reiterated a Buy rating on the stock with a $6.00 price target.

See today’s best-performing stocks on TipRanks >>

Nurix Therapeutics (NRIX)

In a report released today, Gil Blum from Needham reiterated a Buy rating on Nurix Therapeutics, with a price target of $31.00. The company’s shares closed last Tuesday at $14.83.

According to TipRanks.com, Blum is a 3-star analyst with an average return of 2.4% and a 41.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Mereo Biopharma Group Plc, and Crispr Therapeutics AG.

Nurix Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.67, a 69.6% upside from current levels. In a report released yesterday, Stephens also assigned a Buy rating to the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on UNCY:

• Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
• These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
• Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
• Unicycive Therapeutics initiated with an Overweight at Piper Sandler
• Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update